Medtronic has received CE Mark approval for the commercial sale of the Endeavor drug-eluting coronary stent with the rapid exchange delivery system in European Union member countries, including the UK and Ireland, where the new medical device is manufactured. The Endeavor system – the first cobalt alloy platform on the drug-eluting stent (DES) market – offers best in class deliverability, excellent clinical results and a strong patient safety profile.
Drug-eluting stent gains CE approval
“We are very pleased to provide physicians and patients with Medtronic’s high performance Endeavor drug-eluting stent system”, said Scott Ward, president of Medtronic Vascular. “Physicians will now have a broader choice among the drug-eluting stents that are available to treat their patients. We believe the Endeavor system offers a powerful combination of deliverability, efficacy and safety that is unmatched by any other commercially available stent.”
